Clinical Trials
15 trialsNCT00640978 2025-05-01
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05904457 2023-06-15
BRISK
Asan Medical Center
Phase 2 Unknown
NCT00591123 2021-10-01
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00696696 2016-06-30
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
NYU Langone Health
Phase 2 Completed
NCT01703910 2015-10-09
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase 2 Completed
NCT00769067 2015-10-07
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
Pfizer
Phase 2 Completed
NCT00642746 2014-09-26
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00081614 2014-05-16
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00385398 2013-09-02
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00554775 2011-12-12
TACTIC
University College, London
Phase 2 Terminated
NCT00784667 2010-11-30
Dux
Austin Health
Phase 2 Unknown
NCT00125021 2009-11-02
Tarceva and Capecitabine for Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00123851 2009-04-28
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00116506 2007-12-21
Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed